Ignite Creation Date:
2024-05-06 @ 3:53 AM
Last Modification Date:
2024-10-26 @ 11:40 AM
Study NCT ID:
NCT02401347
Status:
COMPLETED
Last Update Posted:
2023-02-21
First Post:
2015-03-24
Brief Title:
Phase II Trial of Talazoparib in BRCA12 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
Sponsor:
Melinda Telli
Organization:
Stanford University
Organization Data
Organization:
Stanford University
Class:
OTHER
Study ID:
IRB-31913
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Melinda Telli
Lead Sponsor Class:
OTHER
Responsible Party:
Melinda Telli
Responsible Party Title:
Assistant Professor of Medicine
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Stanford University
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| BioMarin Pharmaceutical | INDUSTRY |
| Pfizer | INDUSTRY |